Yazar "Arslan, Cagatay" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    Cancer of Unknown Primary Presenting With a Giant Shoulder Mass in a Young Man: Prostate Adenocarcinoma
    (Kare Publ, 2018) Atilla, Fatos Dilan; Topaloglu, Omercan; Pala, Emel Ebru; Arslan, Cagatay
    Cancer of unknown primary (CUP) is a metastatic tumor for which a standardized diagnostic workup fails to identify the site of origin at the time of making the diagnosis. The most frequent primary origin site is the lung and pancreas (40%), and the second most frequent primary origin site is the gastrointestinal system. For male patients with CUP, serum prostate specific antigen (PSA) level and free PSA/total PSA ratio should be determined; if necessary, immunohistochemical staining for PSA and P504S should be performed from the metastatic mass. Young patients with CUP should be attentively evaluated to establish the diagnosis and start treatment. We report the case of a young man who presented with a giant shoulder mass of unknown primary site and was diagnosed as having prostate adenocarcinoma.
  • Küçük Resim
    Öğe
    Cancer of unknown primary presenting with a giant shoulder mass in a young man: prostateadenocarcinoma
    (Kare publ, concord ıstanbul, dumlupınar mah, cıhan sk no 15, b blok 162 kadıkoy, ıstanbul, 00000, turkey, 2018) Atilla, Fatos Dilan; Topaloglu, Omercan; Pala, Emel Ebru; Arslan, Cagatay
    Cancer of unknown primary (CUP) is a metastatic tumor for which a standardized diagnostic workup fails to identify the site of origin at the time of making the diagnosis. The most frequent primary origin site is the lung and pancreas (40%), and the second most frequent primary origin site is the gastrointestinal system. For male patients with CUP, serum prostate specific antigen (PSA) level and free PSA/total PSA ratio should be determined; if necessary, immunohistochemical staining for PSA and P504S should be performed from the metastatic mass. Young patients with CUP should be attentively evaluated to establish the diagnosis and start treatment. We report the case of a young man who presented with a giant shoulder mass of unknown primary site and was diagnosed as having prostate adenocarcinoma.
  • Küçük Resim Yok
    Öğe
    Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC
    (Sage Publications Ltd, 2024) Yildirim, Mahmut Emre; Karadurmus, Nuri; Okten, Ilker Nihat; Turk, Haci Mehmet; Urakci, Zuhat; Arslan, Cagatay; Celik, Sinemis
    Backgrounds and Objectives Colorectal cancer is one of the leading causes of mortality both globally and in our country. In Turkey, we conducted a multicenter investigation into the effectiveness of second-line treatments and real-life data for patients with RAS wild-type metastatic colorectal cancer (NCT04757311).Materials and Methods In this retrospective analysis, records from 28 centers were collected, and histopathological, molecular, and clinical characteristics were documented. Patients were categorized into groups based on their second-line biological treatments: anti-EGFR (Group A and Group B, panitumumab and cetuximab) and anti-VEGF (Group C, bevacizumab and aflibercept). They were then compared within these groups.Results A total of 588 patients with documented RAS wild-type status were evaluated. The median OS was 15.7, 14.3 and 14.7 months in Group A, Group B and Group C, respectively (p = 0.764). The median PFS of the patients in second-line setting that received panitumumab, cetuximab and bevacizumab/aflibercept were 7.8, 6.6 and 7.4 months, respectively (p = 0.848).Conclusion According to the results of our real-life data study, there is no significant difference in efficiency between the combination of biological agent and chemotherapy used in the second-line treatments.